Puerto Rican chemical industry news

13 April 2026

Genmab: Rina‑S plus bevacizumab tolerable in advanced ovarian cancer

RAINFOL‑01 D2 (n=40): common TEAEs—nausea 80%, fatigue 67.5%, anemia 55%, neutropenia 45%; serious TEAEs 15%; dose reductions 27.5%; no fatal TEAEs. Phase 3 RAINFOL‑04 ongoing.
12 April 2026

GSK Mo‑Rez (B7‑H4 ADC) achieves 62% ORR in platinum‑resistant ovarian and 67% in endometrial cancer

BEHOLD-1 phase I: Mo-Rez (B7-H4 ADC) active across expression levels; manageable hematologic toxicity and nausea. 5.8 mg/kg recommended; five Phase III trials planned 2026
6 April 2026

Amgen reports positive Phase 3 topline results for subcutaneous TEPEZZA in moderate-to-severe thyroid eye disease

Phase 3 subcutaneous TEPEZZA met primary endpoint in moderate-to-severe TED: 76.7% proptosis response vs 19.6% placebo; mean −3.17 mm reduction; safety consistent; mild injection-site AEs
2 April 2026

FDA approves Lilly's Foundayo (orforglipron), oral GLP‑1 for anytime dosing

Oral GLP‑1 produced ~12% mean weight loss (~27 lb) at 72 weeks in Phase 3. Available via direct home delivery with low‑cost copays; carries thyroid tumor and GI side‑effect warnings.
30 March 2026

Siemens USA appoints Ann Fairchild President & CEO

Ann Fairchild, with 25+ years at the company, named permanent president & CEO of its U.S. unit; will oversee ~50,000 employees and $24B revenue, focusing on AI, infrastructure and reshoring.
28 March 2026

Amgen: Repatha cuts first major cardiovascular events 31% in high‑risk patients without significant atherosclerosis

VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.

How does the Puerto Rican chemical industry perform?

Find out with chemXplore Alpha

Learn more